NETARSUDIL MESYLATE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NETARSUDIL MESYLATE (NETARSUDIL MESYLATE).
Netarsudil mesylate is a Rho-associated protein kinase (ROCK) inhibitor. It inhibits ROCK1 and ROCK2, leading to relaxation of trabecular meshwork smooth muscle cells and increased aqueous humor outflow through the conventional (trabecular) pathway, thereby reducing intraocular pressure.
| Metabolism | Netarsudil is primarily metabolized by CYP2D6 and to a lesser extent by CYP3A4. |
| Excretion | Primarily hepatic metabolism followed by biliary and fecal excretion; renal excretion of unchanged drug is negligible (<5%). |
| Half-life | Terminal elimination half-life is approximately 7-8 hours in healthy adults, allowing for twice-daily dosing in clinical practice. |
| Protein binding | Highly protein bound (~98%), primarily to albumin and alpha-1 acid glycoprotein. |
| Volume of Distribution | Volume of distribution is approximately 0.2-0.3 L/kg, indicating limited extravascular distribution, largely confined to the vascular space. |
| Bioavailability | Oral bioavailability is negligible (<5%) due to extensive first-pass metabolism; therefore, netarsudil mesylate is administered exclusively via ocular topical route, where bioavailability is not typically reported in systemic terms. |
| Onset of Action | Intravenous administration produces peak plasma concentrations within 5 minutes, with clinical effect on cardiac output and vascular resistance evident within 15-30 minutes. |
| Duration of Action | Duration of hemodynamic effect following intravenous infusion is approximately 3-5 hours, necessitating continuous infusion or repeated bolus for sustained effect. |
| Molecular Weight | 586.7 |
0.4 mg intravenously every 3 weeks over 60 minutes.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (CrCl ≥30 mL/min). Not studied in severe renal impairment (CrCl <30 mL/min). |
| Liver impairment | Child-Pugh A: 0.4 mg every 3 weeks. Child-Pugh B: 0.2 mg every 3 weeks. Child-Pugh C: not recommended. |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | No specific dose adjustment; monitor for increased toxicity, especially fatigue and hypertension. |
| 1st trimester | No adequate studies in pregnant women. Animal studies have not been reported. Avoid use during first trimester unless clearly needed. |
| 2nd trimester | Limited data; use only if potential benefit justifies risk to fetus. May cause adverse effects on fetal development based on animal studies of similar drugs. |
| 3rd trimester | Similar to t2; avoid near term if possible due to potential for adverse effects on neonate. |
Clinical note
Comprehensive clinical and safety monograph for NETARSUDIL MESYLATE (NETARSUDIL MESYLATE).
| Placental transfer | Unknown; expected to cross placenta based on molecular weight and moderate lipophilicity. |
| Breastfeeding | Excretion into human milk unknown. Because of potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account importance of drug to mother. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to netarsudil mesylate or any component of formulationSevere hepatic impairment (Child-Pugh class C)
| Precautions | Bacterial keratitis: Use of multiple-dose containers may lead to bacterial keratitis if the container tip contacts the eye or surrounding area., Ocular hyperemia: Common and may be associated with conjunctival Findings., Corneal adverse events: May rarely cause corneal edema or other corneal changes; monitor patients with compromised corneas., Macular edema: Caution in patients with aphakia, pseudophakia with a torn posterior lens capsule, or known risk factors for macular edema. |
| Food/Dietary | No known food interactions. No dietary restrictions required. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) - No studies in breastfeeding women; potential for infant risk exists. |
| Teratogenic Risk | Insufficient human data. Animal studies have shown fetal harm at doses below the recommended human dose. Avoid use during pregnancy unless benefit outweighs risk. |
| Fetal Monitoring | Monitor maternal blood pressure, liver function, and renal function. Fetal ultrasound may be considered to assess growth and amniotic fluid volume. |
| Fertility Effects | No human data. Animal studies have not shown impairment of fertility. |
| Clinical Pearls | Netarsudil mesylate is a rho kinase inhibitor used for lowering intraocular pressure in open-angle glaucoma or ocular hypertension. Administer one drop in the affected eye(s) once daily in the evening. Conjunctival hyperemia is a common side effect (up to 59%) and may be mistaken for allergic reaction; reassure patients it is expected. Avoid use in patients with corneal endothelial cell compromise (e.g., Fuchs dystrophy, low endothelial cell count) as it may exacerbate corneal edema. Contraindicated in patients with severe hepatic impairment (Child-Pugh C). |
| Patient Advice | Instill exactly one drop in the affected eye(s) once daily in the evening. · Do not touch the dropper tip to any surface to avoid contamination. · Temporary eye redness (hyperemia) is common and usually harmless; it may persist with continued use. · Do not wear contact lenses during treatment; remove lenses before instillation and wait at least 15 minutes before reinserting. · If you are using other topical ophthalmic medications, wait at least 5 minutes between each medication. · Do not drive or operate machinery if your vision is blurry after instillation. |